Artificial intelligence might soon be capable of discovering how to develop better treatments for psychiatric disorders.
What’s happening:
- BullFrog AI (NASDAQ: BFRG) recently announced potentially breakthrough results from their collaboration with the Lieber Institute for Brain Development that leverages artificial intelligence to better understand psychiatric disorders
- The collaboration brings together proprietary data from the Lieber Institute for Brain Development and BullFrog AI’s innovative artificial intelligence platform to cluster subjects based solely on biological data and not behavioural diagnoses
Why it matters:
- By focusing on biological data and commonalities between a large sample size of different brains, BullFrog AI is able to uncover insights at the gene level which previously were not possible without artificial intelligence and machine learning
- If BullFrog AI is able to successfully identify biological subtypes within specific disorders it could unlock entirely new approaches to therapeutic treatments and drug development for many different mental health conditions
By the numbers:
- The Lieber Institute for Brain Development gave BullFrog AI access to their proprietary data of more than 2,800 brain samples
Going deeper:
- The Lieber Institute for Brain Development owns the largest collection of brain samples for research and scientific study in the world
Market reaction:
- Shares of BullFrog AI are up more than +150% since the announcement of their early results for their collaboration with the Lieber Institute for Brain Development
